ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER THERAPIES

Title:

ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER THERAPIES

Document Type and Number:

WIPO Patent Application WO2003039486

Kind Code:

A3

Abstract:

Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.

Inventors:

HARIHARAN KANDASAMY (US)
HANNA NABIL (US)

Application Number:

PCT/US2002/036226

Publication Date:

December 31, 2003

Filing Date:

November 12, 2002

Export Citation:

Click for automatic bibliography generation Help

Assignee:

IDEC PHARMA CORP (US)
HARIHARAN KANDASAMY (US)
HANNA NABIL (US)

International Classes:

A61K39/395; A61P35/00; A61P35/02; C07K16/28; (IPC1-7): A61K39/395; C07K16/28

Domestic Patent References:

WO2001074388A1	2001-10-11
WO1998019706A1	1998-05-14

Foreign References:

US20010018041A1

2001-08-30

Download PDF:

View/Download PDF PDF Help

Previous Patent: STABLE LIQUID PHARMACEUTICAL FORMULATION OF IGG ANTIBODIES

Next Patent: CYCLO(PROLYL-GLYCINE) AND METHODS OF USE TO TREAT NEURAL DISORDERS